Vistagen Therapeutics, Inc.
جودة البيانات: 83%
VTGN
NASDAQ
Manufacturing
Chemicals
KWD 0.56
▲
KWD 0.00
(0.74%)
القيمة السوقية: 22.15 M
السعر
KWD 0.56
القيمة السوقية
22.15 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Negative free cash flow of -60.30 M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-114.36%
أقل من متوسط القطاع (-53.58%)
ROIC-92.96%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio4.67
Interest CoverageN/A
التقييم
PE (TTM|NTM)
-0.33 | -0.49
أعلى من متوسط القطاع (-1.48)
P/B Ratio0.43
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1366 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1366 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -0.3 | -1.5 |
| P/B | 0.4 | 1.6 |
| ROE % | -114.4 | -53.6 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
3 محللين
Hold
الحالي
KWD 0.56
المستهدف
KWD 0.97
KWD 0.90
KWD 1.00
KWD 1.00
التوقعات
مكرر الربحية المستقبلي
-0.49
ربحية السهم المستقبلية
-KWD 1.13
الإيرادات المقدّرة
242,400.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.13
-KWD 1.60 – -KWD 0.68
|
242,400.0 | 4 |
| FY2026 |
-KWD 1.71
-KWD 1.82 – -KWD 1.59
|
1.05 M | 3 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.30
-KWD 0.44 – -KWD 0.17
|
75,750.0 | 4 |
| 2026 Q1 |
-KWD 0.27
-KWD 0.37 – -KWD 0.17
|
220,600.0 | 3 |
مفاجآت الأرباح
آخر 6 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.49 | -KWD 0.45 | +7.2% |
| Q32025 | -KWD 0.44 | -KWD 0.54 | -22.7% |
| Q22025 | -KWD 0.44 | -KWD 0.47 | -6.8% |
| Q12025 | -KWD 0.49 | -KWD 0.44 | +10.2% |
| 2026-Q2 | -KWD 0.30 | -KWD 0.55 | -84.9% |
| 2026-Q1 | -KWD 0.27 | -KWD 0.47 | -74.1% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -67.05 M |
| ROE | -114.36% | ROA | -91.85% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -60.30 M |
| ROIC | -92.96% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4.67 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 49.72 M | Tangible Book Value | 50.92 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.33 | Forward P/E | -0.49 |
| P/B Ratio | 0.43 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 91.37 | Fwd Earnings Yield | N/A |
| FCF Yield | -272.25% | ||
| Market Cap | 22.15 M | Enterprise Value | -25.22 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.90 | Revenue / Share | N/A |
| FCF / Share | -1.52 | OCF / Share | -1.52 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 89.94% |
| SBC-Adj. FCF | -64.49 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | -227,000.0 | 1.11 M | 1.09 M |
| Net Income | -51.42 M | -29.36 M | -59.25 M | -47.76 M | -17.93 M |
| EPS (Diluted) | -1.67 | -1.52 | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -55.97 M | -33.02 M | -59.27 M | -47.78 M | -17.93 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 39.38 M | 20.02 M | 44.38 M | 35.41 M | 12.48 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 150,000.0 | 127,000.0 | 129,500.0 | 153,500.0 | 117,600.0 |
| Interest Expense | — | — | 26,200.0 | 19,900.0 | 1,600.0 |
| Income Tax | 7,000.0 | 4,000.0 | 5,900.0 | 3,400.0 | 2,600.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 84.34 M | 123.65 M | 21.09 M | 74.64 M | 108.28 M |
| Total Liabilities | 13.95 M | 9.37 M | 9.01 M | 9.93 M | 16.30 M |
| Shareholders' Equity | 70.39 M | 114.29 M | 12.08 M | 64.72 M | 91.98 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 67.13 M | 119.17 M | 16.64 M | 68.14 M | 103.11 M |
| Current Assets | 82.08 M | 120.67 M | 17.51 M | 71.00 M | 104.12 M |
| Current Liabilities | 12.61 M | 5.12 M | 4.57 M | 5.77 M | 4.19 M |
{"event":"ticker_viewed","properties":{"ticker":"VTGN","listing_kind":"stock","pathname":"/stocks/vtgn","exchange":"NASDAQ","country":"US"}}

